Biosimilars Pathway Seen As Part Of Health Care Reform Debate Next Year
Executive Summary
The potential for cost savings from biosimilars is likely to entangle the debate over a pathway for their approval into the discussion on health care reform that will unfold in the next Congress
You may also be interested in...
Obama Budget Counts On FOB Savings For Health Reform – But How, And How Much, Are Open Questions
FDA would receive funds to create infrastructure for allowing drug reimportation, under sketch of 2010 budget.
Senate Biosimilars Bill Readied For Take-Off In Next Congress
Kennedy will enter 111th Congress with a ready-to-go bill after committee officially reports out S. 1695 last week.
Biosimilars Create Class-wide Competition, German Experience Finds
Follow-on biologics may be able to achieve broader market penetration if they are not deemed to be interchangeable or substitutable for a single reference product, according to Novartis